Clinical practice guideline for chronic myelogenous leukemia and its practice in China
- VernacularTitle:慢性髓性白血病临床诊疗指南与中国实践
- Author:
Hao JIANG
;
Xiaojun HUANG
- Publication Type:Journal Article
- Keywords:
chronic myelogenous leukemia;
hematopoetic stem cell transplantation;
imatinib
- From:
Chinese Journal of Practical Internal Medicine
2003;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
Imatinib mesylate,as the first generation Bcr-Abl tyrosine kinase inhibitor,has brought revolutionary treatment for Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML);it has been recommended as the first-line treatment for CML by NCCN Practice Guidelines in Oncology in 2008 and European LeukemiaNet(ELN) criteria.However,imatinib has three limitations:first,it is expensive and can not be stopped if efficancy to be maintained;Second,some 20%~30% of patients develope resistance to imatinib;and third,the CML patients can not be cured with imatinib.Taking into consideration of the situation in China,we recommend individual therapy using TKI,HSCT,interferon and cytotoxic drugs for CML patients in China.
